Harmesh Naik, MD. Hope Cancer Clinic
|
|
- Tobias Chandler
- 5 years ago
- Views:
Transcription
1 Harmesh Naik, MD. Hope Cancer Clinic
2 A brief review of adjuvant therapy of breast cancer Summarize selected new developments in adjuvant therapy of breast cancer Discussion is limited to early stage breast cancer (non metastatic)
3 Reduce the risk of cancer recurrence Improve overall survival Improve/maintain quality of life and minimize long term toxicity an important goal Prevention of new cancer
4 Determine risk of recurrence Determine appropriate treatment based on risk
5 Clinical trial evaluation Standard therapy
6 High risk Aggressive therapy Chemotherapy, anti HER-2 therapy, combination therapy Low risk Low toxicity therapy Hormonal therapy Int risk Individualized Molecular markers, patient choice
7 HER2 positive Chemotherapy + Anti HER 2 based therapy (e.g. Trastuzumab) ER/PR positive ER/PR neg HER 2 neg Hormonal therapy Chemotherapy
8 Node positive, HER 2 negative AC-T, TAC, CAF, A-T-C Prefer dose dense Node negative, HER 2 negative All of above CMF HER 2 positive AC-TH TCH
9 Pre-menopausal Tamoxifen Ovarian suppression if TAM is refused Post menopausal AI agent (preferred) Tamoxifen (rarely)
10
11
12 Patient 1 : A 51 yrs old, Right breast carcinoma, 4.5 cm. T2aN1a, IIB. One node positive. ER/PR strongly positive, HER-2 was +3 by IHC. What is the best systemic therapy option? 1. Systemic chemotherapy alone 2. Systemic chemotherapy + Herceptin 3. Herceptin alone 4. Hormonal therapy alone 5. Systemic chemotherapy + Herceptin + Hormonal therapy 6. None
13 Chemotherapy + Herceptin + Hormonal therapy with an AI agent for 5 years. S/P dose dense AC x 4 weekly Paclitaxel and Herceptin x 12 weekly Herceptin x 36 additional weeks.
14 Patient 2: A 68 yrs old, right breast cancer, Node positive T2N1, IIB ER PR positive, HER 2 negative. What is the best systemic therapy option? 1. Systemic chemotherapy alone 2. Systemic chemotherapy + Herceptin 3. Hormonal therapy alone 4. Systemic chemotherapy + Hormonal therapy 5. None
15 Chemotherapy + Hormonal therapy. AC x 4 Paclitaxel x 4.
16 Patient 3 : A 61 year old female. Breast cancer, T2N0M0, Stage IIA, pectoralis muscle involvement. Node negative. ER positive, HER-2 negative. What is the best systemic therapy option? 1. Systemic chemotherapy alone 2. Hormonal therapy alone 3. Systemic chemotherapy + Herceptin 4. Systemic chemotherapy + Hormonal therapy 5. None
17 Oncotype DX assay report indicated 10 year recurrence risk of 10% and recurrence score of 16. Chemotherapy is not clearly indicated in this situation Hormonal therapy alone (an AI agent) for 5 years
18 Biology of individual breast cancer as determined by gene expression determines clinical behavior and risk of cancer recurrence and thus, prognosis. This may allow individualized treatments based on unique genetic blueprint (genetic signature) of individual cancer Help identifying patients who are likely to respond to certain treatments - choose specific treatment Help identifying patients who aren't likely to respond or tolerate to certain treatment - minimize ineffective or toxic treatment and choose alternative treatment
19 Tamoxifen was an example of targeted therapy based on Estrogen receptor (ER) status
20 Risk assessment (Prediction of outcomes) Selection of best treatment Best outcome
21
22 Ross, J. S. et al. Oncologist 2008;13:
23 Ross, J. S. et al. Oncologist 2008;13:
24 Ross, J. S. et al. Oncologist 2008;13:
25 Ross, J. S. et al. Oncologist 2008;13:
26 Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer by Jeffrey S. Ross et al in The Oncologist, Vol. 13, No. 5, , May 2008; doi: /theoncologist
27 Oncotype DX (21 gene assay) Mammaprint (70 gene signature) Rotterdam Signature (76 gene assay) Many more are in development There may be too many markers and methods creating confusion on optimal marker Most of the new methods have yet to be validated in large prospective clinical trials
28 A 21 gene RT-PCR assay performed on formalin fixed paraffin embedded tissue Recurrence score and % probability of recurrence Identifies high risk patients who would benefit from chemotherapy and who would not Helps select a group of patient who could avoid morbidity and cost of adjuvant chemotherapy
29
30 Already in use for node negative, ER positive patients to assess risk of recurrence and to determine need for chemotherapy Cost is nearly $ 3000 (estimate)
31 16 Cancer and 5 Reference Genes From 3 Studies PROLIFERATION Ki-67 STK15 Survivin Cyclin B1 MYBL2 INVASION Stromelysin 3 Cathepsin L2 ESTROGEN ER PR Bcl2 SCUBE2 GSTM1 CD68 BAG1 HER2 GRB7 HER2 REFERENCE Beta-actin GAPDH RPLPO GUS TFRC Paik et al. N Engl J Med. 2004;351:
32 Calculation of the Recurrence Score Result RS = Coefficient x Expression Level x HER2 Group Score x ER Group Score x Proliferation Group Score x Invasion Group Score x CD x GSTM1 Category RS (0-100) x BAG1 Low risk RS <18 Int risk RS 18 and <31 High risk RS 31 Paik et al. N Engl J Med. 2004;351:
33 Soonmyung Paik, M.D et al: NEJM: 2004: Volume 351:
34 P < patients Paik et al. N Engl J Med. 2004;351:
35 High risk node negative group (Recurrence score over 31) appears to have similar risk of recurrence as node positive group Paik et al. N Engl J Med. 2004;351:
36 Soonmyung Paik, M.D et al: NEJM: 2004: Volume 351:
37 Node positive patients: traditionally gets chemotherapy Retrospective analysis of SWOG 8814 study Node positive, ER positive patients 40% were low risk by Oncotype DX (score <18) CAF-T has no benefit over TAM alone in this group Albain K et al: Lancet oncology: on line published on
38 Intermediate risk (score 18-30): no benefit of chemotherapy over Tamoxifen High risk 31% patient (score over 31):Chemotherapy was beneficial (10 year DFS) 10 year OS in high risk: 68% for chemo versus 51 % for Tamoxifen Replicated data in node positive patients Need prospective studies
39 Low recurrence score patients: No benefit from chemotherapy High recurrence score patients: Clear cut benefit from chemotherapy Data for node positive subset is similar to prior node negative data by Paik et al. Caution: Prospective data is still needed for node positive group
40 The Oncotype DX assay is recommended for use in newly diagnosed ER+, N- breast cancer patients to predict risk of recurrence. The assay can also be used to identify patients who may be successfully treated with tamoxifen and may not require adjuvant chemotherapy. It has been suggested that tamoxifen-treated patients with an excellent estimated prognosis may be spared adjuvant chemotherapy. Harris L et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):
41 The option of using a gene-based assay of tumor tissue (Oncotype DX, Genomic Health) to help guide chemotherapy treatment decisions is now included within the systemic adjuvant treatment decision pathway for patients with node-negative or pn1mi (micrometastasis: 0.2 mm mm), hormone-receptor-positive, HER2- negative tumors that are 0.6 to 1.0 cm and moderately/poorly differentiated or with unfavorable features or > 1 cm. NCCN Clinical Practice Guidelines in Oncology Breast Cancer, (Version )
42 My practice: Reserve for HER negative, ER/PR positive, node negative patients Order Oncotype DX assay only if it is going to help in decision making. Do not order the test if patient does not want chemotherapy regardless of results Will now consider for selected node positive
43
44 ER receptor (ER-α66) predicts response to Tamoxifen (currently measured) About 40% ER positive tumors fail to respond to Tamoxifen ER α 66 positive Tumors over expressing a variant ER-α36 are less likely to respond to Tamoxifen Alternative treatment strategy is needed (?AI agents, chemotherapy) for ER-α36 positive L. Shi et al. JCO: 27: 3423-July 2009.
45 ER-α36, a Novel Variant of ER-α, is Expressed in ER-positive and -negative Human Breast Carcinomas. Lisa Lee et al: Anticancer Res ; 28(1B):
46 ER 36 positive ER 66 negative ER 36 positive ER 66 negative ER-α36, a Novel Variant of ER-α, is Expressed in ER-positive and -negative Human Breast Carcinomas. Lisa Lee et al: Anticancer Res ; 28(1B):
47 Poor metabolizer or mutant CYP2D6 low or completely deficient levels of CYP2D6 fail to activate tamoxifen and thus are unable to benefit from its antitumor effects Variants of CYP enzymes leads to poor metabolism of Tamoxifen and lower level of Endoxifen May be seen in up to 10% of Caucasians May predict lack of response to Tamoxifen Clinical breast cancer: Vol 9 (4) Nov 2009:
48 Drugs can affect Tamoxifen metabolism Avoid strong or intermediate inhibitors of CYP2D6 reduces Tamoxifen metabolism Testing for CYP2D6 is available Not yet recommended in NCCN guidelines Need prospective data
49 Strong inhibitors Paroxetine (Paxil) Fluoxetine (Prozac) Intermediate inhibitors Sertraline Cimetidine Amiodorone Doxepin Ticlopidine Haloperidol
50 This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription Localized to chromosome 17 (in proximity of HER-2 gene TOP2A and HER-2 co amplification seen in 8% breast cancer TOP2α may provide clues to who benefits from Anthracyclines
51 HER 2 positive cancers are considered more sensitive to Anthracycline based regimen BCIRG 006 data: Not conclusive. No diff between AC-TH or TCH MA 5 trial - Topo IIA amplification correlated with improved survival with Epirubicin (Pritchard et al: NEJM 354: 2103, CALGB 8541: topo IIA amplifications fail to predict response (L. Harris et al: JCO 27: ) Conflicting data Need prospective data. Not ready for clinical use yet
52 Low rate of CR to neo-adjuvant therapy with AT or CMF in women with breast cancer and BRCA 1 mutation Intermediate CR rate with AC or FAC Higher CR rate after treatment with Cisplatin based regimens Need further studies T. Byrski et al. JCO: 28:
53
54 A DNA microarray is a collection of microscopic DNA spots attached to a solid surface A DNA microarray is also commonly known as gene chip, DNA chip, or biochip DNA microarrays are created by robotic machines that arrange minuscule amounts of hundreds or thousands of gene sequences on a single microscope slide DNA microarrays are used to simultaneously measure the expression of large numbers of genes.
55 Collect the messenger RNA molecules present in cells. Label each mrna molecule by attaching a fluorescent dye. Place the labeled mrna onto a DNA microarray slide. The messenger RNA will hybridize - or bind - to its complementary DNA on the microarray, leaving its fluorescent tag. Use a special scanner to measure the fluorescent areas on the microarray. Figure accessed in
56 Dr. Stuart Schreiber at
57 The thumbnail-sized devices are microscopic grids that have pieces of DNA representing every gene in the human genome stuck on them. Scientists use them to measure the activity of our 20,000-plus genes at the same time.
58 Dr. Eric Lander at
59
60 Gene expression values from microarray experiments are represented as heat maps to visualize the result of data analysis. Accessed in
61 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Sørlie T et al. Proc National Acad Sciences 2001;98: doi: /pnas PNAS September 11, 2001 vol. 98 no
62 Sørlie T et al. PNAS 2001;98: Gene expression patterns of 85 experimental samples representing 78 carcinomas, three benign tumors, and four normal tissues, analyzed by hierarchical clustering using the 476 cdna intrinsic clone set. Tumor subtypes Full cluster ERB B2 cluster Basal cell cluster Normal like cluster Luminal cluster
63 Comparison of experimental sample-associated dendrograms from two different hierarchical clustering analyses. Sørlie T et al. PNAS 2001;98:
64 Sørlie T et al. PNAS 2001;98: Overall and relapse-free survival analysis of the 49 breast cancer patients, uniformly treated in a prospective study, based on different gene expression classification. Luminal A cluster Basal cell cluster
65 CALGB 9344: AC versus AC-T in node positive high risk breast cancer (Henderson IC et al, JCO 21: : 2003) Five biomarkers evaluated by IHC on tissue microarrays-er, HER2, Ki-67, CK5/6, EGFR Formaldehyde fixed specimens 2151 patients with node positive cancers Patients were grouped in to 4 breast cancer subtypes Nielsen TO et al: ASCO Bca symposium October 2009: Abstract 23. Clinical breast cancer: Vol 9 (4) Nov 2009:
66 Subtype ER HER2 KI 67 CK 5 or EGFR Luminal A + - Low Luminal B + + High HER2 enriched - + Core basal Clinical breast cancer: Vol 9 (4) Nov 2009:
67 Subtype No. pts Med RFS yrs RFS (AC-T vs AC) P value Luminal A 790 NR Luminal B HER2 enriched Core basal ER -ve, HER-2 -ve Clinical breast cancer: Vol 9 (4) Nov 2009:
68 Tumor subtypes identified by tissue microarray predicted prognosis Luminal A subtype had favorable outcome Basal or HER-2 enriched subtypes had poorer outcomes Clinical breast cancer: Vol 9 (4) Nov 2009:
69 Tumor subtypes identified by tissue microarray predicted benefit from Paclitaxel Core Basal subtype, HER-2 enriched subtype and Luminal B : improvement in RFS with Paclitaxel Luminal A: no benefit from paclitaxel Verified a prior subset analysis that ER+, HER-2 neg group may not benefit form paclitaxel addition to AC Clinical breast cancer: Vol 9 (4) Nov 2009:
70
71 Docetaxel-Carboplatin-Trastuzumab versus AC-TH versus AC- T (began in 2001) Herceptin is indicated in HER 2 positive breast cancer with high risk features: e.g. ER/PR negative ER positive + Tumor size over 2 cm ER positive + Age less than 35 years ER positive +Nuclear grade 2 of 3 Herceptin prescribing information 2009
72 AC-TH TCH AC-T Hazard ratio Risk of rec (36% reduction) (25% reduction) baseline DFS 65mon 84% 81% 75% Heart failure 2% 0.4% 0.3% 21/1068 pts 4 / 1056 pts 7/1050 pts Leukemia 7 pts 1 pt 2 pts Slamon D et al: San Antonio breast conference Clinical breast cancer: Vol 10 (1) Feb 2010:
73 AC-TH DCH AC-T yr DFS
74 TCH and AC-TH both are good adjuvant alternatives for HER 2 positive patients Each regimen has pros and cons AC-TH is slightly superior but appears more toxic Individualize selection. Young patients:? Favor AC-TH TCH provides an alternative to AC-TH in patients with increased risk for cardiac toxicity or for those who wants less visits
75 NCCTG N 9831 clinical trial results AC-T versus AC-T-H sequential versus AC+TH concurrent Concurrent arm has 25% improvement in DFS compared to sequential arm AC-TH Concurrent is preferred regimen Toxicity is not affected by this schedule Dr. E. Perez-San Antonio Breast conference 2009 Clinical breast cancer: Vol 10 (1) Feb 2010:
76 AC-T AC-T-H AC-TH DFS at 5 years Dr. E. Perez-San Antonio Breast conference 2009
77 Risk of breast cancer recurrence in Tamoxifen treated patients 15% at 5 years 33% at 15 years Risk of recurrence continued beyond 5 years (EBCTCG data Lancet 2005: 365: 1687)
78 Tamoxifen Years 1-5 Tamoxifen Years 1-5 Extended Letrozole Years 6-10 Interval 1-3 years Delayed extended Letrozole
79 Beneficial in pre menopausal women who becomes post menopausal on or after Tamoxifen 4 year DFS: 10.1% advantage in Letrozole group over placebo Low risk node negative patients also benefited Supports use of extended Letrozole for those who meet definition of post menopausal Dr. P. Goss-San Antonio Breast conference 2009 Clinical breast cancer: Vol 10 (1) Feb 2010: 19-26
80 4 year DFS Diff in % Pre menopausal Post menopausal All pts 10 3 Node positive 10 7 Node negative yr distant DFS 5 2.5
81 Early pre-menopausal breast cancer: ER positive The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer an absolute reduction of 3.2 percentage points and a relative reduction of 36% in the risk of disease progression Michael Gnant, M.D., NEJM: 2009: Volume 360:
82
83
84 78 patients 70 genes Disease free Distant mets Disease free Distant mets Gene expression profiling predicts clinical outcome of breast cancer : Laura J. van 't Veer, et al: Nature 415, (31 January 2002)
85 98 patients 550 ER reporter genes ER +ve signature ER -ve signature 38 ER neg 100 BRCA 1 rep genes BRCA1 signature BRCA1 negative Gene expression profiling predicts clinical outcome of breast cancer : Laura J. van 't Veer, et al: Nature 415, (31 January 2002)
86
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationIs Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013
Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Changing Phases claudin low Lum A Lum B Basal Her2 NIH Consensus Development Panel,
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More information30 years of progress in cancer research
Breast Cancer Molecular Knowledge Integrated in Clinical Practice Personalized Medicine Laura J. Esserman UCSF Comprehensive Cancer Center Retreat Breast Cancer Management Advances 80-90s 1) Screening
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationRationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York
Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationShe counts on your breast cancer expertise at the most vulnerable time of her life.
HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationBreast Cancer Heterogeneity
Breast Cancer Heterogeneity Session 2: 8:15 AM 9:00 AM Molecular Subsets and Molecular Diagnostics in Breast Cancer ER + subtypes ER-negative subtypes Lisa A. Carey, MD University of North Carolina Lineberger
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationOncotype DX reveals the underlying biology that changes treatment decisions 37% of the time
Oncotype DX reveals the underlying biology that changes treatment decisions 37% of the time Even when treatment decisions based on traditional measures seem conclusive, Oncotype DX can lead to a different
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More informationTAILORx: Established and Potential Implications for Clinical Practice
TAILORx: Established and Potential Implications for Clinical Practice Joseph A. Sparano, MD Study Chair, TAILORx Vice-Chair, ECOG-ACRIN Cancer Research Group Hello Healthcare Summit Berlin, Germany March
More informationProfili di espressione genica
Profili di espressione genica Giampaolo Bianchini MD Ospedale San Raffaele, Milan - Italy Gene expression profiles Transcriptomics Gene DNA mrna mirnas Protein metilation Metabolite Genomics Transcriptomics
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationIII Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama
III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina Farmacogenomica y Cancer de Mama Vicente Valero, M.D., F.A.C.P. Professor of Medicine Deputy
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationOVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER
OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationGENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN
GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN Adam Brufsky, MD, PhD Professor of Medicine Associate Chief, Hematology-Oncology Associate Director, Clinical Investigation University
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationGenomic platforms in breast cancer
Genomic platforms in breast cancer Prof. Miguel Martín Instituto de Investigación Sanitaria Hospital Gregorio Marañón Universidad Complutense Madrid mmartin@geicam.org Disclosure Dr. Martin has received
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationThe Current Status and the Future Prospects of Multigene testing in Europe
The Current Status and the Future Prospects of Multigene testing in Europe Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam St. Gallen Recommendations 2009 =
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationHigh False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX
High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study DAVID J DABBS, MD Professor and Chief of Pathology
More informationMaking Understanding Molecular Profiles Less Painful. Presenter Disclosure Information
Welcome to Master Class for Oncologists Miami, FL December 18, 2009 Session 1: 1:00 PM - 1:45 PM Towards Personalized Medicine in Breast Cancer: Understanding Molecular Subtypes and the Role of Diagnostics
More informationTHE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE. Dr Husam Marashi 03/02/2017
THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE Dr Husam Marashi 03/02/2017 THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER TODAY S TALK: CENTRE EXPERIENCE
More informationModern classification of breast cancer-should we stick with morphology or convert to molecular profiles?
Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept
More informationBiologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University
Biologic Subtypes and Prognos5c Factors Claudine Isaacs, MD Georgetown University Prognos5c Factor Defini5on Predicts outcome in absence of systemic therapy Thus tell us when (not how) to treat a pa5ent
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes
Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationJanet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario
Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design
More informationComparison of prognostic signatures for ER positive breast cancer in TransATAC:
Comparison of prognostic signatures for ER positive breast cancer in TransATAC: EndoPredict, a high performance test in node negative and node positive disease Ivana Sestak, PhD Centre for Cancer Prevention
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationCase Study Oncotype DX Breast Cancer Assay
Case Study Oncotype DX Breast Cancer Assay Steven Shak, MD Chief Medical Officer, Genomic Health IOM Workshop on the Review of Omics-Based Tests November 16, 2010 Trastuzumab For Herceptest Positive Breast
More informationBreast cancer pathology
Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters
More informationTherapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
More informationCurrent Status and Future Development of Tools for Prognosis and Prediction - USA
Current Status and Future Development of Tools for Prognosis and Prediction - USA John H. Ward, MD Professor of Medicine University of Utah School of Medicine Huntsman Cancer Institute October18, 2009
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationProfili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI
Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo BREAST CANCER Brain Adjuvant Medical Therapies
More informationSection: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014
Medical Policy Manual Topic: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Date of Origin: October 5, 2004 Section: Genetic Testing Last
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationNon-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Contents Role of Anthracyclines in adjuvant treatment EBCTCG2012
More informationSession thématisée Les Innovations diagnostiques en cancérologie
10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest 10-12 mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer
More informationFrom bio-guided to personalized oncology
From bio-guided to personalized oncology Rafii A Département de chirurgie Gynécologique, université de montpellier Department of Genetic Medicine, WCMC NO CONFLICT OF INTEREST Personalized genomic based
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationSession II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair
Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair Symposium: Innovation in Breast Cancer 2014 Madrid, Spain February 21, 2014 Cancer
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More information